We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Detecto

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
16 Feb 2023 - 18 Feb 2023

Novel Breath-Based Diagnostics Could Indicate Early Rejection of Organs in Lung Transplant Patients

By HospiMedica International staff writers
Posted on 26 Jan 2022
Print article
Image: BreathBiopsy Collection Station (Photo courtesy of Owlstone Medical)
Image: BreathBiopsy Collection Station (Photo courtesy of Owlstone Medical)

SQI Diagnostics Inc. (Ontario, Canada) and Owlstone Medical (Cambridge, UK) have signed a Memorandum of Understanding (MOU) to work together on the discovery, development and commercialization of breath-based biomarkers relating to invasive aspergillus lung infection and lung transplant rejection.

SQI develops and manufactures respiratory health and precision medicine tests while Owlstone is a global leader in Breath Biopsy for applications in early disease detection and precision medicine. Fungal lung infection is a large risk for certain vulnerable people such as transplant patients, where one-year survival rates for invasive aspergillosis following lung transplant is only 59%. This is largely because antifungal therapies are not appropriate for patients who are on immunosuppressants, and so early and reliable diagnosis of fungal infection is critical.

The current gold-standard diagnostic procedures for lung transplant rejection require the regular collection of tissue samples from the lung, which is invasive, expensive and can lead to serious complications. Hence, there is a clear need for a better solution. Owlstone’s non-invasive Breath Biopsy platform represents a better approach to current methods, which alongside SQI's deep experience in lung transplant diagnostics will be used to identify and deploy novel breath-based biomarkers that can indicate early rejection of organs in lung transplant patients.

Owlstone is conducting independent clinical trials to validate breath-based volatile organic compounds to diagnose Invasive Aspergillosis with high levels of performance. SQI and Owlstone will agree on the most appropriate regulatory strategy for the tests and, as necessary, liaise with the appropriate regulatory authorities to seek approval of the breath collector as a medical device and/or the approval of the lung transplant rejection in vitro diagnostic test (IVD). Owlstone will own and patent any inventions arising from the lung transplant rejection discoveries and offer an exclusive, worldwide license to SQI to commercialize the biomarkers for clinical use. SQI will undertake reasonable commercial efforts to develop and commercialize the lung transplant rejection test.

"With SQI's strategic interest in lung transplant biomarkers, we're excited to collaborate with Owlstone in applying the discovery, development and commercialization of biomarkers of acute cellular rejection and perhaps chronic rejection," said Andrew Morris, President and CEO of SQI Diagnostics. "This MOU can help further establish SQI's leadership in commercializing diagnostic testing for healthcare professionals and patients as we extend SQI's diagnostics across the continuum of care for organ transplant patients."

Related Links:
SQI Diagnostics Inc. 
Owlstone Medical

New
Platinum Supplier
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Endoscopy Display
EndoVue Plus 24”
New
Handheld POC Ultrasound
P09
New
Flexible Examination Light
ri-magic LED

Print article

Channels

AI

view channel
Image: A novel research study moves the needle on predicting coronary artery disease (Photo courtesy of Pexels)

AI-Enabled ECG Analysis Predicts Heart Attack Risk Nearly as well as CT Scans

Increased coronary artery calcium is a marker of coronary artery disease that can lead to a heart attack. Traditionally, CT scans are used to diagnose buildup of coronary artery calcium, although CT scanners... Read more

Critical Care

view channel
Image: New spray fights infections and antibiotic resistance (Photo courtesy of Chalmers University of Technology)

Hydrogel-Based Spray Kills Antibiotic-Resistant Bacteria in Wounds and Biomedical Implants

Antibiotic resistance has been ranked among the top ten threats to global health by the World Health Organization (WHO). Antibiotic-resistant bacteria is estimated to cause almost 1.3 million deaths annually... Read more

Surgical Techniques

view channel
Image: The Inspira aspiration catheter has received CE Mark approval (Photo courtesy of Infinity Neuro)

Innovative Aspiration Catheter for Treatment of Stroke Delivers Next-Level Navigation Performance

Stroke is a disease that affects the arteries within and leading to the brain. Globally, stroke is the second-leading cause of death and the third-leading cause of death and disability combined.... Read more

Health IT

view channel
Image: Using digital data can improve health outcomes (Photo courtesy of Unsplash)

Electronic Health Records May Be Key to Improving Patient Care, Study Finds

When a patient gets transferred from a hospital to a nearby specialist or rehabilitation facility, it is often difficult for personnel at the new facility to access the patient’s electronic health records... Read more

Point of Care

view channel
Image: Steripath improves the diagnostic accuracy and timeliness of sepsis test results (Photo courtesy of Magnolia)

All-in-One Device Reduces False-Positive Diagnostic Test Results for Bloodstream Infections

Blood cultures are considered the gold standard diagnostic test for the detection of blood stream infections, such as sepsis. However, positive blood culture results can be frequently wrong, and about... Read more

Business

view channel
Image: Researchers expect broader adoption of AI in healthcare in the near future (Photo courtesy of Pexels)

Artificial Intelligence (AI) Could Save U.S. Healthcare Industry USD 360 Billion Annually

The wider adoption of artificial intelligence (AI) in healthcare could save the U.S. up to USD 360 billion annually although its uptake in the industry is presently limited owing to the absence of trust... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.